Armata Pharmaceuticals, Inc.(ARMP)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ARMP Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Armata Pharmaceuticals, Inc. (ARMP), a Healthcare sector company. ARMP is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Armata Pharmaceuticals, Inc. reports net income of $74.1M, free cash flow of $-8.7M. Top institutional holders of ARMP by reported 13-F value include Madison Asset Management, BlackRock, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. ARMP trades on the NYSE exchange and files with the SEC under CIK 921114. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ARMP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Armata Pharmaceuticals, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$74.1M
Free Cash Flow
Q2 2026
$-8.7M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-818.8% YoYOperating Income
+13.7% YoYEPS (Diluted)
-439.3% YoYTotal Assets
-11.1% YoYOp. Cash Flow
+31.4% YoYFree Cash Flow
+33.3% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-173.8M -818.8% | $-18.9M +72.6% | $-69.0M -87.0% | $-36.9M -59.4% | $-23.2M -4.4% | $-22.2M |
| Operating Income | $-36.6M +13.7% | $-42.4M -3.8% | $-40.9M -10.7% | $-36.9M -55.1% | $-23.8M -10.4% | $-21.6M |
| EPS (Diluted) | $-4.80 -439.3% | $-0.89 +53.4% | $-1.91 -76.9% | $-1.08 -12.5% | $-0.96 +28.9% | $-1.35 |
| Total Assets | $76.9M -11.1% | $86.4M -12.1% | $98.4M +2.6% | $95.8M +37.4% | $69.8M +76.6% | $39.5M |
| Operating Cash Flow | $-25.8M +31.4% | $-37.6M +20.8% | $-47.4M -46.0% | $-32.5M -37.8% | $-23.6M -29.0% | $-18.3M |
| Free Cash Flow | $-26.3M +33.3% | $-39.4M +29.0% | $-55.6M -60.2% | $-34.7M -39.4% | $-24.9M -30.3% | $-19.1M |
Get alerted when ARMP's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Armata Pharmaceuticals, Inc. including:
Top Institutional Holders of ARMP
Madison Asset Management, LLC
$13.7M2,107,175 shBlackRock, Inc.
$3.6M559,986 shVANGUARD CAPITAL MANAGEMENT LLC
$3.2M487,968 shMILLENNIUM MANAGEMENT LLC
$3.0M470,500 shGEODE CAPITAL MANAGEMENT, LLC
$1.8M270,550 shDauntless Investment Group, LLC
$1.3M203,891 shSTATE STREET CORP
$839.8K129,600 shNORTHERN TRUST CORP
$581.8K89,791 shVANGUARD PORTFOLIO MANAGEMENT LLC
$527.2K81,354 shEDGEWOOD MANAGEMENT LLC
$518.4K80,000 sh
| Fund | Value | Shares |
|---|---|---|
| Madison Asset Management, LLC | $13.7M | 2,107,175 |
| BlackRock, Inc. | $3.6M | 559,986 |
| VANGUARD CAPITAL MANAGEMENT LLC | $3.2M | 487,968 |
| MILLENNIUM MANAGEMENT LLC | $3.0M | 470,500 |
| GEODE CAPITAL MANAGEMENT, LLC | $1.8M | 270,550 |
| Dauntless Investment Group, LLC | $1.3M | 203,891 |
| STATE STREET CORP | $839.8K | 129,600 |
| NORTHERN TRUST CORP | $581.8K | 89,791 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $527.2K | 81,354 |
| EDGEWOOD MANAGEMENT LLC | $518.4K | 80,000 |
More Healthcare Companies
View all Healthcare →Put ARMP on your watchlist
Track score changes the day Armata Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ARMP a good stock to buy?
13F Pro's AI-powered analysis of Armata Pharmaceuticals, Inc. (ARMP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ARMP are available on the ARMP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ARMP is classified as a small company.
Which hedge funds own ARMP?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ARMP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Armata Pharmaceuticals, Inc.'s investment landscape.